Nishimura, K.; Konishi, T.; Ochi, T.; Watanabe, R.; Noda, T.; Fukumoto, T.; Miura, N.; Miyauchi, Y.; Kikugawa, T.; Takenaka, K.;
et al. CD21lo B Cells Could Be a Potential Predictor of Immune-Related Adverse Events in Renal Cell Carcinoma. J. Pers. Med. 2022, 12, 888.
https://doi.org/10.3390/jpm12060888
AMA Style
Nishimura K, Konishi T, Ochi T, Watanabe R, Noda T, Fukumoto T, Miura N, Miyauchi Y, Kikugawa T, Takenaka K,
et al. CD21lo B Cells Could Be a Potential Predictor of Immune-Related Adverse Events in Renal Cell Carcinoma. Journal of Personalized Medicine. 2022; 12(6):888.
https://doi.org/10.3390/jpm12060888
Chicago/Turabian Style
Nishimura, Kenichi, Tatsuya Konishi, Toshiki Ochi, Ryuta Watanabe, Terutaka Noda, Tetsuya Fukumoto, Noriyoshi Miura, Yuki Miyauchi, Tadahiko Kikugawa, Katsuto Takenaka,
and et al. 2022. "CD21lo B Cells Could Be a Potential Predictor of Immune-Related Adverse Events in Renal Cell Carcinoma" Journal of Personalized Medicine 12, no. 6: 888.
https://doi.org/10.3390/jpm12060888
APA Style
Nishimura, K., Konishi, T., Ochi, T., Watanabe, R., Noda, T., Fukumoto, T., Miura, N., Miyauchi, Y., Kikugawa, T., Takenaka, K., & Saika, T.
(2022). CD21lo B Cells Could Be a Potential Predictor of Immune-Related Adverse Events in Renal Cell Carcinoma. Journal of Personalized Medicine, 12(6), 888.
https://doi.org/10.3390/jpm12060888
